SIRT6 in Cancer: Mechanistic Insights into Its Dual Roles in Cancer Biology and Implications for Precision Therapeutic Development
Sirtuin 6 (SIRT6), a (Nicotinamide adenine dinucleotide) NAD<sup>+</sup>-dependent deacylase and mono- (adenosine diphosphate) ADP-ribosyltransferase, is increasingly recognized as a pivotal regulator of genomic stability, metabolic reprogramming, and epigenetic remodeling. This review synthesizes current evidence on the dual roles of SIRT6 in cancer, highlighting its context-dependent functions as both a tumor suppressor and promoter across various malignancies. We detail its involvement in DNA damage sensing, repair coordination, glycolytic regulation, and chromatin modification, and discuss how these mechanisms contribute to tumor initiation, progression, and therapy resistance. Emerging therapeutic strategies targeting SIRT6, including small-molecule modulators, genetic interventions, and combination therapies, are critically evaluated. Our analysis underscores the necessity for context-specific therapeutic targeting, and pharmacological modulation of SIRT6 represents a promising avenue for precision oncology.
Authors
- Jie Xin Tong (ORCID: https://orcid.org/0000-0002-7613-9039)
- Zimin Han (ORCID: https://orcid.org/0009-0006-2438-5621)
- Kunrui Zhu
- Yanqi Feng
- Yuelin Han
- Shu Xia (ORCID: https://orcid.org/0000-0001-8421-453X)
- Xiangtian Xiao (ORCID: https://orcid.org/0009-0004-9447-3366)
- Yiming Li (ORCID: https://orcid.org/0000-0002-0393-1818)
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Biomolecules
- Published
- 2025-11-26
- DOI
- https://doi.org/10.3390/biom15121655
- Primary Topic
- Sirtuins and Resveratrol in Medicine
- Type
- article
- Field-Weighted Citation Impact
- 0.00